Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
VNDA 
Vanda Pharmaceuticals Inc (VNDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: VNDA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.62
1 Year Target Price $13.62
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.64% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 433.18M USD | Price to earnings Ratio - | 1Y Target Price 13.62 |
Price to earnings Ratio - | 1Y Target Price 13.62 | ||
Volume (30-day avg) 3 | Beta 0.6 | 52 Weeks Range 3.81 - 9.60 | Updated Date 01/10/2026 |
52 Weeks Range 3.81 - 9.60 | Updated Date 01/10/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -39.7% | Operating Margin (TTM) -55.61% |
Management Effectiveness
Return on Assets (TTM) -12.15% | Return on Equity (TTM) -16.72% |
Valuation
Trailing PE - | Forward PE 103.09 | Enterprise Value 150341297 | Price to Sales(TTM) 2.04 |
Enterprise Value 150341297 | Price to Sales(TTM) 2.04 | ||
Enterprise Value to Revenue 0.71 | Enterprise Value to EBITDA 12.91 | Shares Outstanding 59096630 | Shares Floating 49330912 |
Shares Outstanding 59096630 | Shares Floating 49330912 | ||
Percent Insiders 7.21 | Percent Institutions 77.67 |
Upturn AI SWOT
Vanda Pharmaceuticals Inc
Company Overview
History and Background
Vanda Pharmaceuticals Inc. was founded in 2001. It is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with unmet medical needs. Key milestones include the FDA approval of HETLIOZu00ae (tasimelteon) for Non-24-Hour Sleep-Wake Disorder and LENVIMAu00ae (lenvatinib mesylate) in combination with everolimus for advanced renal cell carcinoma (in partnership).
Core Business Areas
- Therapeutic Areas: Vanda Pharmaceuticals Inc. focuses on developing and commercializing treatments for disorders of the central nervous system (CNS), particularly sleep disorders and other CNS-related conditions.
- Product Commercialization: The company is responsible for the commercialization and marketing of its approved products in the United States.
Leadership and Structure
Vanda Pharmaceuticals Inc. is led by a management team including a Chief Executive Officer, Chief Medical Officer, Chief Financial Officer, and other key executives. The company operates as a publicly traded entity with a Board of Directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Competitors: Eisai Inc. (Dayvigo),Merck & Co., Inc. (Belsomra)
- Market Share Data: [object Object]
- Product Name 1: HETLIOZu00ae (tasimelteon): Approved for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in blind adults and children and adults with Smith-Magenis Syndrome (SMS). Competitors include other sleep aids and therapies for circadian rhythm disorders. Market share data is proprietary and not publicly disclosed, but it is a leading treatment for Non-24. Annual revenue from HETLIOZu00ae was $220.5 million in 2023.
- Competitors: Neurable Inc.,Cognix Systems
- Market Share Data: [object Object]
- Product Name 2: QEEG-Guided Neuromodulation: While not a single product, Vanda is involved in the development and application of advanced neuromodulation techniques guided by quantitative electroencephalography (qEEG) for various neurological and psychiatric conditions. Specific product names and market share are not applicable as this represents a technology platform.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly regulated and characterized by long development cycles, significant R&D investment, and patent protection. The CNS therapeutics market, in particular, is driven by an aging population, increasing prevalence of neurological disorders, and a demand for effective treatments for sleep and mental health conditions.
Positioning
Vanda Pharmaceuticals Inc. is positioned as a niche player focusing on specialized CNS disorders with unmet medical needs. Its competitive advantages lie in its proprietary technologies, established regulatory pathways for its approved products, and its ability to identify and develop treatments for rare or underserved patient populations.
Total Addressable Market (TAM)
The TAM for sleep disorders is substantial, with estimates varying widely depending on the specific condition and geographic region, but often in the tens of billions of USD globally. For Non-24, the TAM is smaller due to its rarity, but Vanda's position as a pioneer in this area gives it a significant share of that specific niche.
Upturn SWOT Analysis
Strengths
- Proprietary technology and drug candidates
- Approved products with established market presence (HETLIOZu00ae)
- Experienced management team with a focus on CNS disorders
- Strong R&D pipeline
- Expertise in navigating regulatory pathways
Weaknesses
- Dependence on a limited number of products
- High R&D costs and long development timelines
- Potential for patent expirations and generic competition
- Limited commercial reach compared to larger pharmaceutical companies
Opportunities
- Expansion of approved indications for existing products
- Development of new drug candidates for CNS disorders
- Partnerships and collaborations to expand R&D and commercialization capabilities
- Growth in emerging markets
- Increasing awareness and diagnosis of sleep disorders
Threats
- Regulatory hurdles and delays in drug approval
- Intense competition from established pharmaceutical companies and emerging biotechs
- Pricing pressures and reimbursement challenges
- Adverse clinical trial results
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- Eisai Inc. (US Stock Symbol: ESALF)
- Merck & Co., Inc. (US Stock Symbol: MRK)
- Sumitomo Pharma Co., Ltd. (US Stock Symbol: SMNHY)
Competitive Landscape
Vanda Pharmaceuticals Inc. holds a strong position in the niche market of Non-24-Hour Sleep-Wake Disorder with HETLIOZu00ae. Its advantage lies in its focused approach and established market presence for this indication. However, it faces competition from larger pharmaceutical companies with broader portfolios and significant R&D resources in the general CNS and sleep disorder space.
Growth Trajectory and Initiatives
Historical Growth: Vanda Pharmaceuticals Inc. has shown consistent revenue growth over the past few years, primarily attributed to the increasing adoption and sales of HETLIOZu00ae. However, net income has been more volatile due to significant investments in its pipeline.
Future Projections: Analyst projections for Vanda Pharmaceuticals Inc. generally anticipate continued revenue growth, driven by the expansion of HETLIOZu00ae and potential future product launches. Profitability projections are contingent on successful R&D outcomes and effective cost management.
Recent Initiatives: Recent initiatives include the ongoing clinical development of novel drug candidates, efforts to expand the commercial reach of HETLIOZu00ae, and strategic partnerships aimed at advancing its pipeline.
Summary
Vanda Pharmaceuticals Inc. is a focused biopharmaceutical company with a strong presence in the niche market of Non-24-Hour Sleep-Wake Disorder. Its flagship product, HETLIOZu00ae, drives its revenue, and the company shows potential for growth through its R&D pipeline. However, it faces risks associated with product dependency, high R&D costs, and competition from larger players, necessitating careful management of its resources and strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Vanda Pharmaceuticals Inc. SEC Filings (10-K, 10-Q)
- Company Investor Relations Websites
- Financial Data Providers (e.g., Refinitiv, Bloomberg - aggregated)
- Industry Research Reports (e.g., Grand View Research, MarketsandMarkets - aggregated)
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. All data is subject to change and should be independently verified. Market share data is based on industry estimates and proprietary information where applicable. Historical financial data and projections are not guarantees of future performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vanda Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2006-04-12 | Founder, President, CEO & Chairman of The Board Dr. Mihael H. Polymeropoulos M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 368 | Website https://www.vandapharma.com |
Full time employees 368 | Website https://www.vandapharma.com | ||
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.